pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ASTELLAS · news · pharmadog
← back to ASTELLAS
News mentioning ASTELLAS
44
stories
1d
Cellares and Ori Biotech’s new cell therapy manufacturing contracts
endpoints
2d
Sling banks $123M for an experimental thyroid eye disease pill
biopharma dive
2d
Sionna says good-bye to 46% of staffers, including exec
biospace
2d
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
endpoints
3d
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
fiercebiotech
8d
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
16d
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
biospace
17d
Mid-cap biotechs join Trump’s latest round of drug pricing deals
biopharma dive
17d
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
17d
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
18d
STAT+: Trump strikes nine more deals with drugmakers to lower prices
stat
24d
Will a ‘reset’ reignite investment in women’s health startups?
biopharma dive
Aug 13, 26
PTC takes a chance on Sangamo’s Fabry disease gene therapy
biopharma dive
Aug 13, 26
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
biospace
Aug 13, 26
PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market
fiercebiotech
Aug 12, 26
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
Aug 11, 26
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
biospace
Aug 10, 26
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
fiercebiotech
Aug 5, 26
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
Jul 22, 26
AI data becomes sticking point in biopharma dealmaking
biospace
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 13, 26
Agenus surges on study pivot; Apnimed lines up an IPO
biopharma dive
May 15, 26
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
biopharma dive
May 15, 26
STAT+: Top U.S. officials pressured Germany to pay more for prescription drugs
stat
May 14, 26
AstraZeneca follows Merck with Phase 3 win in bladder cancer
endpoints
May 13, 26
STAT+: Drug meant to make gene therapy safer may also make it less effective
stat
May 12, 26
STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
stat
May 12, 26
STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
stat
May 12, 26
STAT+: Hims’ sales miss as telehealth competition grows
stat
May 12, 26
STAT+: Capsida says it still doesn’t know what caused gene therapy death
stat
← prev
page 1 of 2
next →
